Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category

Leukemia

Volumn 31, Issue 7, 2017, Pages 1562-1569

  Muchtar, E ^a   Dispenzieri, A ^a   Kumar, S K ^a   Ketterling, R P ^a   Dingli, D ^a   Lacy, M Q ^a   Buadi, F K ^a   Hayman, S R ^a   Kapoor, P ^a   Leung, N ^a   Chakraborty, R ^a,b   Gonsalves, W ^a   Warsame, R ^a   Kourelis, T V ^a   Russell, S ^a   Lust, J A ^a   Lin, Y ^a   Go, R S ^a   Zeldenrust, S ^a   Kyle, R A ^a   Rajkumar, S V ^a   Gertz, M A ^a   more..

^a MAYO CLINIC   (United States)

^b Essentia Health St Joseph s Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; MELPHALAN;

ADULT; AGED; AL AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; COHORT ANALYSIS; CYTOGENETICS; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTERPHASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOSOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; TRISOMY; AMYLOIDOSIS; CHROMOSOME 11; CHROMOSOME 14; GENE TRANSLOCATION; GENETICS; MORTALITY; PROCEDURES; PROGNOSIS;

AGED; AMYLOIDOSIS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; MALE; MIDDLE AGED; PROGNOSIS; TRANSLOCATION, GENETIC; TRISOMY;

EID: 85006250831     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.369     Document Type: Article

References (21)

1. Kastritis E, Dimopoulos MA. Recent advances in the management of AL amyloidosis. Br J Haematol 2016; 172: 170-186.
2. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011; 29: 1924-1933.
3. Pardanani A, Witzig TE, Schroeder G, McElroy EA, Fonseca R, Dispenzieri A et al. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 2003; 101: 827-830.
4. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79: 1817-1822.
5. Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR et al. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J 2015; 5: e310.
6. Abraham RS, Ballman KV, Dispenzieri A, Grill DE, Manske MK, Price-Troska TL et al. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood 2005; 105: 794-803.
7. Bochtler T, Hegenbart U, Cremer FW, Heiss C, Benner A, Hose D et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 2008; 111: 4700-4705.
8. Harrison CJ, Mazzullo H, Ross FM, Cheung KL, Gerrard G, Harewood L et al. Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol 2002; 117: 427-435.
9. Hayman SR, Bailey RJ, Jalal SM, Ahmann GJ, Dispenzieri A, Gertz MA et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood 2001; 98: 2266-2268.
10. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 2009; 94: 380-386.
11. Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol 2015; 33: 1371-1378.
12. Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A et al. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after highdose melphalan: a long-term follow-up study. Blood 2016; 128: 594-602.
13. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012; 26: 2317-2325.
14. Gutierrez NC, Garcia JL, Hernandez JM, Lumbreras E, Castellanos M, Rasillo A et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 2004; 104: 2661-2666.
15. Hu Y, Chen W, Chen S, Huang Z. Cytogenetic abnormality in patients with multiple myeloma analyzed by fluorescent in situ hybridization. Onco Targets Ther 2016; 9: 1145-1149.
16. Huang SY, Yao M, Tang JL, Tsay W, Lee FY, Liu MC et al. Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan. Ann Oncol 2005; 16: 1530-1538.
17. Perez-Simon JA, Garcia-Sanz R, Tabernero MD, Almeida J, Gonzalez M, Fernandez-Calvo J et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 1998; 91: 3366-3371.
18. Chretien ML, Corre J, Lauwers-Cances V, Magrangeas F, Cleynen A, Yon E et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood 2015; 126: 2713-2719.
19. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119: 2100-2105.
20. Pawlyn C, Melchor L, Murison A, Wardell CP, Brioli A, Boyle EM et al. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood 2015; 125: 831-840.
21. Bochtler T, Hegenbart U, Kunz C, Benner A, Seckinger A, Dietrich S et al. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid 2014; 21: 9-17.